drugset / Trial / NCT05615467

A Study of Effect of LY3556050 on Metformin in Healthy Participants

NCT05615467

Phase 1 Completed 18 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The main purpose of this study is to evaluate how much Metformin gets into the bloodstream and how long the body takes to get rid of it when it is administered orally in combination with LY3556050 in healthy participants. Iohexol will be administered to evaluate kidney function. Each enrolled participant will remain in the study for up to 7 weeks including the screening period.

Timeline

Start
2022-11-15
Primary completion
2022-12-27
Completion
2022-12-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Iohexol Diagnostic / imaging agent Intravenous
Subject LY3556050 Unknown Oral
Subject Metformin Small molecule Oral

Indications

No indication recorded.